BridgeBio Pharma (BBIO) Divestments (2021 - 2025)
BridgeBio Pharma recorded quarterly Divestments of $2.3 million in Q3 2025, down 91.04% quarter-over-quarter from $25.7 million in Q1 2024.
BridgeBio Pharma's Divestments history runs 3 years deep, the most recent figure standing at $2.3 million for Q3 2025.
- In Q3 2025, Divestments changed N/A year-over-year to $2.3 million; the TTM figure through Dec 2025 stood at $2.3 million (down 91.04% YoY), while the FY2025 annual figure was $2.3 million, down 91.04% from the prior year.
- Divestments came in at $2.3 million for Q3 2025 at BridgeBio Pharma, down from $25.7 million in the prior quarter.
- In the past five years, Divestments ranged from a high of $29.4 million in Q4 2021 to a low of $2.3 million in Q3 2025.
- A 3-year average of $19.1 million and a median of $25.7 million in 2024 frame the typical range for Divestments.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.30 Mn |
| Mar 31, 2024 | 25.68 Mn |
| Dec 31, 2021 | 29.41 Mn |